Personalized management of atrial fibrillation
Fabritz, Larissa; Guasch, Eduard; Sinner, Moritz F; Kirchhof, Paulus

Citation for published version (Harvard):

Link to publication on Research at Birmingham portal

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- Users may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (7)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.
Chapter 57.4  Personalized management of atrial fibrillation
Larissa Fabritz, Eduard Guasch, Moritz Sinner, and Paulus Kirchhof

Summary

◆ Clinical management of patients with atrial fibrillation (AF) today is merely guided by stroke risk, AF pattern, drug safety, and patient-reported symptoms.

◆ To facilitate more personalized treatment of patients with AF, clinical markers reflecting the major causes of AF in patients need to be validated and used in practice.

◆ More personalized and more integrated care will improve outcomes in patients with AF.

Introduction

Atrial fibrillation (AF) is a major cause of cardiovascular morbidity and mortality, despite excellent efforts to improve management.
of patients suffering from the condition. While many strokes can be prevented by oral anticoagulants, heart failure and sudden death remain common, and unplanned hospitalizations contribute further to the burden of AF to affected patients and society. It is well established that different mechanisms cause the arrhythmia in different models of AF, ranging from a genomic predisposition, altered calcium handling, and oxidative stress, to atrial infiltration with fat and fibrous tissue. A similar diversity of the drivers for AF can be found in patients, and several additional ‘vicious circles’ contribute to perpetuation of AF (Figure 57.4.1). Identification of the major drivers of AF in different patient populations, for example, those with AF and heart failure, those with AF due to a genetic predisposition, those with AF and hypertension, those with AF and chronic kidney disease, or those with AF and obesity or metabolic defects, is required to discern specific targets for personalized prevention and therapy of the arrhythmia.

**Current state of atrial fibrillation management**

Clinical risk scores already guide treatment decisions in patients with AF, for example, the CHA$_2$DS$_2$-VASc score that is used to guide oral anticoagulation in AF patients. Other treatment areas are much less established, for example, the optimal type and intensity of ventricular rate control or the optimal rhythm control treatment. Even less is currently known about the best methods to prevent the predicted rise in AF prevalence and incidence. Understanding the major drivers causing AF in different patient populations, for example, those with AF and heart failure, those with AF due to a genetic predisposition, those with AF and hypertension, those with AF and chronic kidney disease, or those with AF and obesity or metabolic defects, is required to discern specific targets for personalized prevention and therapy of the arrhythmia.

**Recent advances underpinning personalized prevention and management of patients with atrial fibrillation**

We have good knowledge of the vicious circles maintaining AF once it has been initiated (Figure 57.4.1). Our knowledge of the major drivers of AF, including drivers of AF that act prior to...
the first episode, has advanced in the last decades. To give a few examples:

- The first genome-wide association study of AF was published a decade ago in 2007, suggesting for the first time an important link between (left) atrial transcription factors such as PITX2 and AF. Further work inspired by this initial observation has delineated a role for such transcription factors for atrial function and genesis of AF.

- In addition to the known effects of atrial dilatation and pressure overload on cellular calcium handling and metabolic homeostasis, recent work has identified relevant roles for subcellular domains for atrial function.

◆ Atrial fibroblasts,18 fat cells,19 and oxidative stress20 have been shown to modulate atrial cardiomyocyte function to create an arrhythmogenic substrate.
◆ Yet other mechanisms cause AF in patients with inherited arrhythmogenic conditions and inherited cardiomyopathies.3

Thus, we have an approximate understanding of the potential drivers for AF in different patients, but we have yet to translate this into stratified approaches to the prevention of AF and management of individual patients with AF.

Development of personalized atrial fibrillation prevention and management

The pathophysiological heterogeneity driving AF and most likely its complications has led to a demand for a new disease taxonomy that better reflects disease mechanisms in AF.4 Genomic and biomedical differences could guide such a taxonomy as well as different social contexts and behavioural patterns (Figure 57.4.2a). It is necessary to describe and classify these drivers in patients, and define a valid taxonomy of different pathophysiological types of AF to underpin the development of stratified approaches to AF management. This requires flexible thinking and interdisciplinary interaction between scientists, clinicians, regulators, funders, and industry partners. Markers for such different types of AF could, for example, be derived from clinical parameters, careful analysis of the electrocardiogram, assessment of blood and urine, and others (Figure 57.4.2b). Importantly, the scientific method used to generate and validate knowledge, that is, identification of novel disease drivers and therapeutic targets, and experimental interventions to demonstrate their physiological relevance, through controlled, randomized clinical trials in patient subpopulations harbouring the identified disease drivers, needs to be upheld to allow robust development of such approaches.

Conclusion

Patients with AF are in need of personalized approaches to prevention and therapy. Interdisciplinary cooperation between scientists, clinicians and other healthcare providers, regulators, industry government agencies, and charities is required, to unleash the potential of personalized management of AF in the future, starting with the development of a new taxonomy of AF based on the major mechanisms causing the arrhythmia in different patients, allowing the identification of novel treatment targets and evaluation of personalized interventions reversing these drivers in clinical trials.

Online resources

For full references and multimedia materials please visit the online version of the book (http://www.oup.com/esccardiomed).

Further reading


